MTIP
AVDL

Magee Thomson Investment Partners’s Avadel Pharmaceuticals AVDL Stock Holding History

Magee Thomson Investment Partners’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-300
Closed -$4K – 103
2015
Q4 		$4K Hold
300
– – ﹤0.01% 76
2015
Q3 		$5K Hold
300
– – ﹤0.01% 43
2015
Q2 		$6K Hold
300
– – ﹤0.01% 47
2015
Q1 		$5K Sell
300
-11,268
-97% -$176K ﹤0.01% 53
2014
Q4 		$199K Buy
11,568
+6,109
+112% +$87.2K 0.05% 57
2014
Q3 		$77K Buy
+5,459
New +$78.5K 0.02% 90

Other funds holding AVDL

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
FPC
Falcon Point Capital San Francisco, California $11.9M AUM 55.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

Magee Thomson Investment Partners's AVDL Position: Q1 2016 in Review

Magee Thomson Investment Partners sold out of Avadel Pharmaceuticals (AVDL) in Q1 2016, closing a stake of 300 shares — an estimated $4K sold.

Magee Thomson Investment Partners first reported a position in AVDL in Q3 2014 and held it in 6 quarters. The position peaked at $199K in Q4 2014. 81 funds tracked by Wall St. Rank hold AVDL as of Q1 2016.

  • Magee Thomson Investment Partners reported no remaining Avadel Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Magee Thomson Investment Partners sold 300 Avadel Pharmaceuticals shares in Q1 2016, an estimated $4K.
  • Magee Thomson Investment Partners first reported a position in Avadel Pharmaceuticals in Q3 2014 and held it in 6 quarters.
  • Magee Thomson Investment Partners's Avadel Pharmaceuticals position peaked at $199K in Q4 2014.
  • 81 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2016.

Based on Magee Thomson Investment Partners's 13F filing for Q1 2016, filed 20 Apr 2016.